Company intelligence / Profile preview
Synchroneuron Inc.
Waltham, Massachusetts, United Statessynchroneuron.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Synchroneuron’s lead candidate, SNC-102—a new formulation of acamprosate calcium—was in Phase 2 trials for moderate-to-severe tardive dyskinesia as of the last major update. The company has focused on improving formulations and understanding pharmacokinetics and mechanism of action through preclinical and open-label studies. No recent clinical results or approvals are reported publicly.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (notably acamprosate calcium/SNC-102)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Synchroneuron Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synchroneuron Inc..